ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1900

Mass Spectrometry-Based Salivary Proteomics For The Discovery Of Novel Diagnostic Biomarkers For Primary Sjögren’s Syndrome and Its Clinical Subsets

Camillo Giacomelli1, Chiara Baldini1, Francesca Sernissi1, Daniela Martini1, Pasquale Pepe2, Nicoletta Luciano1, Francesco Ferro1, Chiara Tani1, Marta Mosca3 and Stefano Bombardieri1, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Institute of Clinical Physiology, National Research Council, Pisa, Italy, 3Rheumatology Unit, University of Pisa, Pisa, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome and proteomics

  • Tweet
  • Email
  • Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Nowadays, the advances of novel proteomic technologies are encouraging research projects for generating reliable diagnostic biomarkers for primary Sjögren’s syndrome (pSS)  to be used in both clinical settings and in clinical trials. Aim of this study was to identify the most significant salivary biomarkers in pSS using proteomic methods and to correlate pSS patients’ salivary proteomic profile to the different histological and immunological aspects of the disease.

Methods: Salivary samples from patients affected by pSS, and sex- and age-matched healthy volunteers (HC) were consecutively collected from May 2012 to February 2013. The ProteinChip System, Series 4000 Personal Edition (Ciphergen Biosystems, Inc) was used to perform SELDI-TOF-MS. The cation exchange array CM10 (Bio-Rad) was selected. Chips were read on a Ciphergen Express Data Manager – Personal Edition (version 3.5). SELDI-TOF-MS data were analyzed by using Mann-Whitney non-parametric test for univariate analysis coupled with a classification and regression tree (CART) algorithm in the multivariate setting. Only significant variables (p<0.05) at the univariate analysis were included in the CART algorithm.

Results: Unstimulated whole saliva samples were collected from 72 consecutive unselected female patients with pSS and from 29 sex- and age- matched HC. A total of 75 peaks were detected at the SELDI-TOF-MS. We found that 25 peaks were significantly different in the pSS patient group with respect to HC (P<0.05). Among these 25 peaks, the selected CART tree indentified 7149 m/z , 7192 m/z, 13507 m/z, 13714 m/z, 16547 m/z, 24059 m/z as best independent biomarkers able to discriminate between pSS and HC with a sensitivity of 96%, a specificity of 70% and a global cross validated error of 29%. Peaks of 7192 m/z, 24059 m/z and two further peaks of 28674 m/z and 33285 m/z were also significantly different in the group of pSS patients with parenchymal inhomogenicity at the salivary gland ultrasonography. Furthermore, in pSS patients with high focus score at the minor salivary gland biopsy and in pSS patients positive for anti-Ro/SSA antibodies, peaks of 4205 m/z and 22232 m/z and peaks of 3502 m/z and 4808 m/z were differently expressed, respectively.

Conclusion: This study supports the use of high throughput technologies to approach the challenge of the discovery of new, accurate diagnostic biomarkers for pSS and its clinical subsets.


Disclosure:

C. Giacomelli,
None;

C. Baldini,
None;

F. Sernissi,
None;

D. Martini,
None;

P. Pepe,
None;

N. Luciano,
None;

F. Ferro,
None;

C. Tani,
None;

M. Mosca,
None;

S. Bombardieri,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mass-spectrometry-based-salivary-proteomics-for-the-discovery-of-novel-diagnostic-biomarkers-for-primary-sjogrens-syndrome-and-its-clinical-subsets/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology